Serum Alpha-Fetoprotein Levels During and After Interferon Therapy and the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

Tamura, Yasushi; Yamagiwa, Satoshi; Aoki, Y.; Kurita, So; Suda, Takafumi; Ohkoshi, Shogo; Nomoto, Minoru; Aoyagi, Yoshinobu

doi:10.1007/s10620-008-0642-y

Cited by 33 publications

(20 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been some reports that AFP is a significant predictor of HCC in patients with chronic hepatitis C [4,5,29]. In addition, it has recently been shown that AFP levels decrease in response to interferon administration in patients with chronic hepatitis C [30,31], and that long-term interferon therapy for aged patients with chronic HCV infection is effective in decreasing serum AFP levels and preventing hepatocarcinogenesis [32,33]. However, little is known about the relationship between changes in serum AFP level over time during interferon therapy and the development of HCC.…”

Section: Introductionmentioning

confidence: 99%

Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The authors suggest that older patients with advanced fibrosis may benefit from prolonged IFN therapy. It is interesting to note that in individuals with HCV who receive IFN therapy AFP levels decline regardless of virologic response (85). AFP levels may decrease by 57% in patients treated with IFN.…”

Section: Hcc and Ifn Maintenance Therapymentioning

confidence: 99%

Viral hepatitis and hepatocellular carcinoma: etiology and management

Zamor

deLemos

Russo

2017

J. Gastrointest. Oncol.

123

107

View full text Add to dashboard Cite

Hepatitis B virus (HBV) risk and hepatocellular carcinoma (HCC) EpidemiologyIt is estimated that over 50% of HCC cases worldwide are related to chronic HBV (1,2). Since the implementation of worldwide HBV vaccination there has been an overall decline in the burden of HBV, yet the HBV burden remains quite high in various parts of the world. There are approximately 350-400 million people across the world infected with HBV, the majority reside in or originate from Asia. Each year HBV accounts for 749,000 new cases of HCC and 692,000 HCC-related deaths (3). The annual incidence of HCC is estimated to be <1% for non-cirrhotic HBV infected patients and 2-3% for those with cirrhosis. Because of worldwide and geographic variations in HBV incidence, the burden of HBV related HCC also varies. Asian-Pacific and sub-Saharan Africa represent the highest incidence of HCC worldwide. Much lower risk of HBV associated HCC is seen in the United States with less than 20% incidence. Due to its diversity, Europe has different areas: low risk (18%) in West and North and high risk (51%) East and South (4). Occult HBV or subclinical infection as defined by detectable HBV DNA in the liver but hepatitis B surface antigen (HBsAg) seronegativity is now recognized as increased risk for HCC. The risk is most notable in those over the age of 50 (5,6). Recently published data reveal that in China, the age-standardized death due to HBV-related HCC and cirrhosis in 2013 was 10.95 and 4.91 per 100,000 people (7). Fifty-five percent of all HCC cases worldwide are reported from China (8).In 1991, the WHO recommended the integration of the HBV vaccine into national immunization programs in countries with an HBV carrier prevalence of 8% or higher by 1995 and in all other countries by 1997 (9). The universal infant vaccination rate in sub-Saharan Africa was initially quite low at 5% in 2000 but increased to 72% by 2012. Parts of the Pacific region had the lowest immunization rates, but by 2012 had increased to the highest rates at 91%. Taiwan has an exceptionally higher This review outlines the various mechanisms and pathophysiology that contributes to this process. There will also be a review on the recommended screening for HCC. Treatment considerations, which are different for these viruses, will be outlined in this review.

show abstract

“…Patients who underwent a liver biopsy and a 75-g oral glucose tolerance test (OGTT) were included in the analysis, while patients taking antidiabetic drugs were excluded. We set the cutoff value for AFP as 10.0 ng/mL because an even slightly elevated AFP level is a risk factor for HCC (6,9). We analyzed factors associated with elevated AFP levels (!…”

Section: Patientsmentioning

confidence: 99%

“…The serum α-fetoprotein (AFP) level is an important predictor of the clinical course in patients with chronic hepatitis C (CHC), as elevated serum AFP levels are associated with a low viral response rate to interferon [IFN (4)], advanced fibrosis (5-7) and a high frequency of HCC (6,(8)(9)(10). Although IFN can lead to biochemical improvement and eradi-cation of HCV, which reduces the risk of HCC (11), the clinical impact of HCV eradication on HCC prevention is less significant in older patients than in younger patients (8).…”

Section: Introductionmentioning

confidence: 99%

Whole-body Insulin Resistance is Associated with Elevated Serum α-fetoprotein Levels in Patients with Chronic Hepatitis C

et al. 2013

View full text Add to dashboard Cite

Objective Little is known about the relationship between elevated serum α-fetoprotein (AFP) levels and insulin resistance, which adversely influence the clinical course of chronic hepatitis C (CHC). Therefore, we investigated the association between serum AFP and insulin resistance in patients with CHC. Methods We retrospectively investigated 300 patients with CHC without hepatoma who underwent liver biopsies and oral glucose tolerance tests. Patients taking antidiabetic drugs were excluded. We analyzed factors associated with elevated AFP levels (! 10.0 ng/mL) in 265 eligible patients. Twenty patients with a homeostasis model assessment for insulin resistance value of ! 2.0 and a whole-body insulin sensitivity index of <5.0 received prospective lifestyle intervention. Results A univariate analysis showed that the body mass index, platelet count, levels of albumin, aspartate aminotransferase, alanine aminotransferase and γ-glutamyl transpeptidase, glucose metabolism, hepatic inflammation, fibrosis and steatosis were associated with elevated AFP levels. In a multivariate analysis, a platelet count of <15×10 4 /μL, aspartate aminotransferase level of ! 50 IU/L, γ-glutamyl transpeptidase level of ! 35 IU/L, whole-body insulin sensitivity index of <5.0 and stage 3-4 fibrosis were independently associated with an elevated AFP level. A Bayesian Network analysis showed that the aspartate aminotransferase level, whole-body insulin sensitivity index and hepatic fibrosis were directly associated with an elevated AFP level. The lifestyle intervention significantly improved the serum AFP level, homeostasis model assessment for insulin resistance and whole-body insulin sensitivity index. Conclusion Whole-body insulin resistance is associated with an elevated serum AFP level in patients with CHC. Lifestyle interventions targeting insulin resistance can reduce the serum AFP level and may ameliorate the clinical course of CHC.

show abstract

Serum Alpha-Fetoprotein Levels During and After Interferon Therapy and the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

Cited by 33 publications

References 38 publications

Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study

Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study

Viral hepatitis and hepatocellular carcinoma: etiology and management

Whole-body Insulin Resistance is Associated with Elevated Serum α-fetoprotein Levels in Patients with Chronic Hepatitis C

Contact Info

Product

Resources

About